Benefits and Limitations of MARD as a Performance Parameter for Continuous Glucose Monitoring in the Interstitial Space

被引：104

作者：

Heinemann, Lutz ^{[1
]}

Schoemaker, Michael ^{[2
]}

Schmelzeisen-Redecker, Guenther ^{[2
]}

Hinzmann, Rolf ^{[2
]}

Kassab, Adham ^{[3
]}

Freckmann, Guido ^{[4
]}

Reiterer, Florian ^{[5
]}

Del Re, Luigi ^{[5
]}

机构：

[1] Sci & Co, Geulenstr 36, D-41462 Neuss, Germany

[2] Roche Diabet Care, Mannheim, Germany

[3] mySugr GmbH, Vienna, Austria

[4] Univ Ulm, Inst Diabet Technol Forsch & Entwicklungsgesell, Ulm, Germany

[5] Johannes Kepler Univ Linz, Linz, Austria

来源：

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY | 2020年 / 14卷 / 01期

关键词：

continuous glucose monitoring; diabetes therapy; quality of measurement; glucose measurement; blood glucose;

D O I：

10.1177/1932296819855670

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

High-quality performance of medical devices for glucose monitoring is important for a safe and efficient usage of this diagnostic option by patients with diabetes. The mean absolute relative difference (MARD) parameter is used most often to characterize the measurement performance of systems for continuous glucose monitoring (CGM). Calculation of this parameter is relatively easy and comparison of the MARD numbers between different CGM systems appears to be straightforward on the first glance. However, a closer look reveals that a number of complex aspects make interpretation of the MARD numbers provided by the manufacturer for their CGM systems difficult. In this review, these aspects are discussed and considerations are made for a systematic and appropriate evaluation of the MARD in clinical trials. The MARD should not be used as the sole parameter to characterize CGM systems, especially when it comes to nonadjunctive usage of such systems.

引用

页码：135 / 150

页数：16

共 57 条

[1] Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes [J].